Class-level differences and within-class heterogeneity in heart failure reporting with immune checkpoint inhibitors: a WHO vigiaccess pharmacovigilance study

9 May 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Heart failure and comorbidities: navigating complex interactions Cardiotoxicity of Drugs Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by